186 results on '"Yoh Matsuoka"'
Search Results
2. Patterns of recurrence in genuine and induced oligometastatic castration‐resistant prostate cancer treated with progressive site‐directed therapy
- Author
-
Soichiro Yoshida, Taro Takahara, Yuki Arita, Kazuma Toda, Koichiro Kimura, Motohiro Fujiwara, Hajime Tanaka, Minato Yokoyama, Yoh Matsuoka, Ryoichi Yoshimura, and Yasuhisa Fujii
- Subjects
Urology - Abstract
To describe oncological outcomes after progressive site-directed therapy (PSDT) in genuine and induced oligometasatic (OM)-castration-resistant prostate cancer (CRPC).Thirty-seven patients with OM-CRPC treated with PSDT were retrospectively analyzed, and oncological outcomes and recurrence patterns on whole-body diffusion-weighted MRI (WB-DWI) were evaluated.Twenty-two (59%) were classified as genuine OM-CRPC and 15 (41%) as induced OM-CRPC. A 50% decline in PSA after PSDT was observed in 21 (95%) genuine OM-CRPCs and 7 (47%) induced OM-CRPCs (p = 0.0005). At a median observation period of 7.3 months, median PSA progression-free survival were 10.9 months in the genuine OM-CRPCs and 4.8 months in the induced OM-CRPCs (p = 0.015). Among the patients who developed PSA progression after PSDT, 11 of 15 in the genuine OM-CRPCs (73%) and 11 of 14 in the induced OM-CRPCs (79%) underwent WB-DWI at PSA progression. The median numbers of newly detected metastases were 2 (range: 1-5) in the genuine OM-CRPCs and 4 (range: 1-40) in the induced OM-CRPCs (p = 0.049). Only one new metastasis appeared in 5 patients from the genuine OM-CRPCs (46%) and 1 from the induced OM-CRPCs (9.1%, p = 0.048). In 7 of 9 patients from the genuine OM-CRPCs (78%) and 7 of 8 patients from the induced OM-CRPCs (88%) who had bone metastases alone, the newly detected metastasis limited to the bone.Genuine OM-CRPC had better oncological outcomes after PSDT than induced OM-CRPC, and the number of lesions detected at recurrence was limited. Induced OM-CRPC might be a disseminated condition with micrometastases at OM diagnosis.
- Published
- 2022
- Full Text
- View/download PDF
3. Succinate dehydrogenase‐deficient malignant paraganglioma complicated by succinate dehydrogenase‐deficient renal cell carcinoma
- Author
-
Yoshitomo Yamaguchi, Minato Yokoyama, Akira Takemoto, Yuki Nakamura, Shohei Fukuda, Sho Uehara, Hajime Tanaka, Soichiro Yoshida, Yoh Matsuoka, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
4. Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side‐specific negative lymph node metastasis at radical prostatectomy
- Author
-
Motohiro Fujiwara, Noboru Numao, Shinya Yamamoto, Yudai Ishikawa, Ryo Fujiwara, Tomohiko Oguchi, Yoshinobu Komai, Yoh Matsuoka, Takeshi Yuasa, and Junji Yonese
- Subjects
Male ,Prostatectomy ,Oncology ,Predictive Value of Tests ,Biopsy ,Lymphatic Metastasis ,Urology ,Prostate ,Humans ,Lymph Node Excision ,Prostatic Neoplasms ,Magnetic Resonance Imaging ,Retrospective Studies - Abstract
Prostate cancer localization is reportedly associated with the laterality of lymph node metastasis. Thus, it may be feasible to predict side-specific lymph node metastasis (LNM) at radical prostatectomy (RP). To investigate whether multiparametric magnetic resonance imaging and biopsy findings can predict side-specific negative LNM and to explore the feasibility of unilateral lymph node dissection (LND) at RP.A total of 500 patients who were diagnosed with prostate cancer with prebiopsy multiparametric magnetic resonance imaging of the prostate and subsequent prostate biopsy and who underwent RP and extended LND without neoadjuvant treatment were enrolled. Multiparametric magnetic resonance imaging, biopsy findings, and LNM were assessed for each side. The negative predictive value (NPV) of multiparametric magnetic resonance imaging or biopsy or both for ipsilateral LNM was examined.LNM was found in 9.2% (46/500) and 15.6% (28/180) of patients in the overall and high-risk cohorts, respectively. Magnetic resonance imaging and biopsy findings were negative in 408 and 262 sides, respectively, in the overall cohort and 144 and 100 sides, respectively, in the high-risk cohort. The NPVs of magnetic resonance imaging, biopsy, and both for ipsilateral LNM were 98.3%, 98.5%, and 99.1%, respectively, in the overall cohort, and 95.8%, 97.1%, and 97.6%, respectively, in the high-risk cohort.Unilateral LND may be indicated based on side-specific LNM risk as assessed by prebiopsy multiparametric magnetic resonance imaging and biopsy.
- Published
- 2022
- Full Text
- View/download PDF
5. Peritoneal closure and the processus vaginalis transection method to prevent inguinal hernia after robot‐assisted radical prostatectomy
- Author
-
Takahiko Soma, Shohei Fukuda, Yusuke Matsuyama, Riko Ikeda, Masaharu Inoue, Yuma Waseda, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Takeo Fujiwara, Yukio Kageyama, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2023
- Full Text
- View/download PDF
6. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society
- Author
-
Varaha S Tammisetti, Peter-Paul Willemse, Daniel Rukstalis, Veeru Kasivisvanathan, Xavier Cathelineau, Yoh Matsuoka, Willemien Van Den Bos, Giorgio Gandaglia, Soroush Rais-Bahrami, Takumi Shiraishi, Massimo Valerio, Ardeshir R. Rastinehad, Cary N. Robertson, Herbert Lepor, Rajan T Gupta, Juan Gomez Rivas, Toshitaka Shin, Ariel Schulman, Yann Barbe, A.L. Abreu, Marco Moschini, Arvin K. George, Marco Oderda, Armando Stabile, Amir H. Lebastchi, Nathan Lawrentschuk, Daniel Margolis, Georg Salomon, M.P. Laguna, Wei Phin Tan, Jean J.M.C.H. de la Rosette, Derek Lomas, Christian P Pavlovich, Hazem Orabi, Bernard Malavaud, Abhinav Sidana, Osamu Ukimura, Sherif Mehralivand, Justin Gregg, Fernando Bianco, Thomas J. Polascik, Jochen Walz, Giancarlo Marra, Petr Macek, Rafael Sanchez-Salas, Sunao Shoji, Mesut Remzi, A. Villers, Radiology and Nuclear Medicine, APH - Personalized Medicine, Marra, Giancarlo, Laguna, Maria Pilar, Walz, Jochen, Pavlovich, Christian P, Bianco, Fernando, Gregg, Justin, Lebastchi, Amir H, Lepor, Herbert, Macek, Petr, Rais-Bahrami, Soroush, Robertson, Cary, Rukstalis, Daniel, Salomon, Georg, Ukimura, Osamu, Abreu, Andre L, Barbe, Yann, Cathelineau, Xavier, Gandaglia, Giorgio, George, Arvin K, Rivas, Juan Gomez, T Gupta, Rajan, Lawrentschuk, Nathan, Kasivisvanathan, Veeru, Lomas, Derek, Malavaud, Bernard, Margolis, Daniel, Matsuoka, Yoh, Mehralivand, Sherif, Moschini, Marco, Oderda, Marco, Orabi, Hazem, Rastinehad, Ardeshir R, Remzi, Mesut, Schulman, Ariel, Shin, Toshitaka, Shiraishi, Takumi, Sidana, Abhinav, Shoji, Sunao, Stabile, Armando, Valerio, Massimo, Tammisetti, Varaha S, Tan, Wei Phin, Van Den Bos, Willemien, Villers, Arnaud, Willemse, Peter-Paul, de la Rosette, Jean, Polascik, Thoma, Sanchez-Salas, Rafael, and Urology
- Subjects
Male ,medicine.medical_specialty ,Scoring system ,Consensus ,Urology ,MEDLINE ,Context (language use) ,Prostate cancer ,SDG 3 - Good Health and Well-being ,Surveys and Questionnaires ,Delphi technique ,medicine ,Biomarkers, tumor ,Prostatic neoplasms cancer ,Biomarkers ,Delphi Technique ,Humans ,Prostatic Neoplasms ,Medical physics ,computer.programming_language ,Tumor ,business.industry ,Subject (documents) ,medicine.disease ,Molecular biomarkers ,Focal therapy ,Nephrology ,business ,computer ,Delphi - Abstract
Background Focal Therapy (FT) for Prostate Cancer (PCa) is promising. However, long-term oncological results are awaited and there is no consensus on follow-up strategies. Molecular biomarkers (MB) may be useful in selecting, treating and following up men undergoing FT, though there is limited evidence in this field to guide practice. We aimed to conduct a consensus meeting, endorsed by the Focal Therapy Society, amongst a large group of experts, to understand the potential utility of MB in FT for localised PCa. Materials and methods A 38-item questionnaire was built following a literature search. The authors then performed three rounds of a Delphi Consensus using DelphiManager, using the GRADE grid scoring system, followed by a face-to-face expert meeting. Three areas of interest were identified and covered concerning MB for FT, i) the current/present role; ii) the potential/future role; iii) the recommended features for future studies. Consensus was defined using a 70% agreement threshold. Results Of 95 invited experts, 42 (44.2%) completed the three Delphi rounds. Twenty-four items reached a consensus and they were then approved at the meeting involving (n=15) experts. Fourteen items reached a consensus on uncertainty, or they did not reach a consensus. They were re-discussed, resulting in a consensus (n=3), a consensus on a partial agreement (n=1), and a consensus on uncertainty (n=10). A final list of statements were derived from the approved and discussed items, with the addition of three generated statements, to provide guidance regarding MB in the context of FT for localised PCa. Research efforts in this field should be considered a priority. Conclusions The present study detailed an initial consensus on the use of MB in FT for PCa. This is until evidence becomes available on the subject.
- Published
- 2022
7. MP51-06 PIRADS SCORE COMBINED WITH POSITIVE CORE NUMBER ON MRI-ULTRASOUND FUSION TARGETED PROSTATE BIOPSY CAN PREDICT THE ABSENCE OF PATHOLOGICAL EXTRAPROSTATIC EXTENSION
- Author
-
Masaki Kobayashi, Yoh Matsuoka, Sho Uehara, Hiroshi Tanaka, Yuki Nakamura, Yusuke Uchida, Shohei Fukuda, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
8. MP50-01 PROGNOSTIC IMPACT OF PATHOLOGICAL RENAL PARENCHYMAL INFILTRATION IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA
- Author
-
Hajime Tanaka, Yuki Fukawa, Kouhei Yamamoto, Shohei Fukuda, Sho Uehara, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Steven C. Campbell, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
9. PD33-05 INCIDENCE AND SIGNIFICANCE OF 20% DECREASE FROM NEW BASELINE ESTIMATED GLOMERULAR FILTRATION RATE AFTER RADICAL AND PARTIAL NEPHRECTOMY
- Author
-
Bo Fan, Minato Yokoyama, Yosuke Yasuda, Yuki Nakamura, Yusuke Uchida, Shohei Fukuda, Sho Uehara, Hajime Tanaka, Soichiro Yoshida, Yoh Matsuoka, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
10. MP24-03 LOCAL RECURRENCE FOLLOWING PARTIAL NEPHRECTOMY IN PATIENTS WITH RENAL CELL CARCINOMA: A MULTICENTER STUDY
- Author
-
Shohei Fukuda, Hajime Tanaka, Kenji Tanabe, Takashi Tamiya, Masaki Kobayashi, Shugo Yajima, Yuki Nakamura, Motohiro Fujiwara, Yudai Ishikawa, Takanobu Yamamoto, Saori Araki, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Yukihiro Otsuka, Fumitaka Koga, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
11. MP52-06 LONGITUDINAL CHANGES IN LOWER URINARY TRACT SYMPTOMS AFTER ARTIFICIAL URETHRAL SPHINCTER IMPLANTATION IN PATIENTS UNDERGOING PRIOR RADIOTHERAPY
- Author
-
Minato Yokoyama, Madoka Kataoka, Yusuke Uchida, Yuki Nakamura, Shohei Fukuda, Sho Uehara, Hajime Tanaka, Soichiro Yoshida, Yoh Matsuoka, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
12. MP53-06 MRI AND MRI-TARGETED BIOPSY CAN DETECT CRIBRIFORM CANCER OF THE PROSTATE
- Author
-
Sho Uehara, Yoh Matsuoka, Kurara Yamamoto, Yuki Nakamura, Yusuke Uchida, Shohei Fukuda, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Kenichi Ohashi, and Yasuhisa Fujii
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
13. Outcomes of gasless laparoendoscopic single‐port partial nephrectomy in 356 consecutive patients: Feasibility of a clampless and sutureless technique
- Author
-
Yasuhisa Fujii, Kazutaka Saito, Hajime Tanaka, Yoh Matsuoka, Soichiro Yoshida, Toshiki Kijima, Sho Uehara, Minato Yokoyama, Kazunori Kihara, and Yosuke Yasuda
- Subjects
medicine.medical_specialty ,Blood transfusion ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Renal function ,Nephrectomy ,03 medical and health sciences ,Pseudoaneurysm ,0302 clinical medicine ,Renal cell carcinoma ,medicine ,Humans ,Dialysis ,Retrospective Studies ,business.industry ,medicine.disease ,Kidney Neoplasms ,Surgery ,Treatment Outcome ,030220 oncology & carcinogenesis ,Feasibility Studies ,Laparoscopy ,Neoplasm Recurrence, Local ,Positive Surgical Margin ,business ,Kidney cancer - Abstract
Objectives To investigate the outcomes and feasibilities of gasless laparoendoscopic single-port clampless sutureless partial nephrectomy. Methods We reviewed 356 consecutive patients with primary unilateral non-metastatic renal masses who underwent gasless laparoendoscopic single-port partial nephrectomy (2011-2018), which was performed retroperitoneally using a three-dimensional flexible endoscope, without vascular clamping or renorrhaphy in principle. Results The median tumor size was 2.5 cm, and 213 (60%), 105 (29%), and 38 (11%) patients had peripheral, central, and hilar tumors, respectively. Clampless and sutureless partial nephrectomy was accomplished in 337 patients (95%), while eight (2%) and 16 (4%) patients required vascular clamping and renorrhaphy, respectively. The median operative time and blood loss were 220 min and 266 mL, respectively; eight patients (2%) received blood transfusion. Clavien-Dindo grade 3a complications occurred in 27 patients (8%); all these patients had urinary leakage treated with ureteral stent placement, one of whom also developed a postoperative pseudoaneurysm. Among 324 patients diagnosed with renal cell carcinoma, six (2%) had positive surgical margins, and one (0.3%) and seven (2%) developed metastatic and local recurrences, respectively. During a median follow-up of 54 months, no patient died from kidney cancer. The median percent decrease in estimated glomerular filtration rate at 3 months after surgery was 5.7%. No patient experienced postoperative acute renal failure, while one patient with preexisting renal impairment started dialysis at 70 months after surgery. Conclusions Clampless and sutureless partial nephrectomy can be safely accomplished in most patients undergoing gasless laparoendoscopic single-port surgery, yielding favorable oncological and functional outcomes.
- Published
- 2020
- Full Text
- View/download PDF
14. METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer
- Author
-
Kazutaka Saito, Taro Takahara, Minato Yokoyama, Yuma Waseda, Yasuhisa Fujii, Yuki Arita, Chikako Ishii, Yoh Matsuoka, Toshiki Kijima, Soichiro Yoshida, and Junichiro Ishioka
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Imaging biomarker ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Bone Neoplasms ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Data Systems ,Humans ,Clinical significance ,Lymph node ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,Taxane ,business.industry ,Bone metastasis ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Prostatic Neoplasms, Castration-Resistant ,Diffusion Magnetic Resonance Imaging ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Disease Progression ,business ,Follow-Up Studies ,Information Systems - Abstract
Background METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) has been proposed as a standard of data acquisition and interpretation for whole-body diffusion-weighted magnetic resonance imaging (WB-DWI) performed in men with advanced prostate cancer. The aim of this study is to demonstrate the clinical significance of the scores in castration-resistant prostate cancer (CRPC). Materials and Methods We retrospectively evaluated WB-DWI obtained from 72 patients with CRPC between 2014 and 2017, when disease progression was suspected at the time of starting a new line of anticancer therapy. Twenty-five (35%) and 30 (42%) patients had a treatment history that included taxane-based chemotherapy and new hormonal drugs, respectively. Results Active bone metastases were identified in 60 patients (83%; number of bone metastasis = 0, 1-2, 3-5, 6-10, and > 10: n = 12 [17%], 20 [28%], 11 [15%], 1 [1%], and 28 [39%], respectively). Progressive lymph node and visceral metastases were identified in 10 (14%) and 4 (6%), respectively. During the median follow-up period of 24 months, 36 (50%) died of prostate cancer. Cancer-specific survival (CSS) was significantly stratified according to the MET-RADS-P scores of osseous metastatic burden and the presence of visceral metastasis (P 10) and the presence of visceral metastasis were significant indicators of shorter CSS (P = .0036 and P = .0017, respectively). Conclusions The extent of bone metastasis and the presence of visceral metastasis on WB-DWI were associated with a shorter CSS in CRPC. MET-RADS-P score can be a prognostic imaging biomarker for CRPC.
- Published
- 2020
- Full Text
- View/download PDF
15. Longitudinal changes in patient‐reported outcomes after artificial urinary sphincter implantation
- Author
-
Hitoshi Masuda, Soichiro Yoshida, Yusuke Uchida, Masahiro Toide, Yuma Waseda, Masaya Ito, Shingo Moriyama, Junichiro Ishioka, Minato Yokoyama, Yasuhisa Fujii, Yoh Matsuoka, Toshiki Kijima, Sho Uehara, and Kazutaka Saito
- Subjects
Male ,medicine.medical_specialty ,Urology ,030232 urology & nephrology ,Urinary incontinence ,Artificial urinary sphincter ,03 medical and health sciences ,0302 clinical medicine ,Lower Urinary Tract Symptoms ,Lower urinary tract symptoms ,medicine ,Humans ,In patient ,Patient Reported Outcome Measures ,Aged ,Retrospective Studies ,030219 obstetrics & reproductive medicine ,business.industry ,Retrospective cohort study ,medicine.disease ,Urinary Incontinence ,Neurology ,Male patient ,Quality of Life ,Urinary Sphincter, Artificial ,Patient-reported outcome ,International Prostate Symptom Score ,medicine.symptom ,business ,Follow-Up Studies - Abstract
OBJECTIVE To evaluate the time course of lower urinary tract symptoms (LUTS) after artificial urinary sphincter (AUS) implantation based on individual longitudinal changes of patient-reported outcomes. METHODS This retrospective study included 66 male patients with severe urinary incontinence who were treated with primary AUS implantation between 2009 and 2019. International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and International Prostate Symptom Score (IPSS) questionnaires were used to evaluate continence status and LUTS preoperatively, 1, 3, and 12 months after activation, and then annually. The annual changes in scores were calculated with a linear mixed model. RESULTS Of the 66 patients, 63 (95%) achieved complete or social continence (number of pads used ≤1/d) at 1 month after activation. Mean preoperative ICIQ-SF, IPSS, and IPSS-quality of life (QOL) score were 18.9, 14.9, and 5.4, respectively; the corresponding scores at 1 month after activation were 4.5, 9.0, and 1.7 (all P
- Published
- 2020
- Full Text
- View/download PDF
16. Feasibility and outcomes of selective tetramodal bladder‐preservation therapy in elderly patients with muscle‐invasive bladder cancer
- Author
-
Junichiro Ishioka, Yasuhisa Fujii, Kazutaka Saito, Yuki Nakamura, Hajime Tanaka, Soichiro Yoshida, Toshiki Kijima, Shugo Yajima, Yoh Matsuoka, Minato Yokoyama, Hiroshi Fukushima, and Sho Uehara
- Subjects
medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Cystectomy ,Bladder preservation ,03 medical and health sciences ,0302 clinical medicine ,Clinical complete response ,Humans ,Medicine ,Neoplasm Invasiveness ,In patient ,Aged ,Bladder cancer ,business.industry ,Muscles ,Muscle invasive ,medicine.disease ,Combined Modality Therapy ,Treatment Outcome ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,Sarcopenia ,Feasibility Studies ,business ,Complication - Abstract
OBJECTIVE To assess the feasibility and functional/oncological outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer. METHODS This study analyzed 154 patients with non-metastatic muscle-invasive bladder cancer who were enrolled into the protocol. After maximal transurethral resection and induction chemoradiotherapy, patients with clinical complete response were offered consolidative partial cystectomy to achieve bladder preservation; otherwise, radical cystectomy was recommended. Postoperative complications, preserved bladder function, and oncological outcomes were compared between elderly (aged ≥75 years) and younger patients (aged
- Published
- 2020
- Full Text
- View/download PDF
17. Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
- Author
-
Minato Yokoyama, Ryoichi Yoshimura, Yasuhisa Fujii, Kazutaka Saito, Kazuma Toda, Yoh Matsuoka, Soichiro Yoshida, Sho Uehara, and Hajime Tanaka
- Subjects
medicine.medical_specialty ,Prostate biopsy ,Urology ,medicine.medical_treatment ,Brachytherapy ,brachytherapy ,hemi‐gland focal therapy ,Salvage therapy ,Case Report ,Case Reports ,prostatic neoplasms ,Prostate cancer ,Prostate ,Medicine ,External beam radiotherapy ,salvage therapy ,radiotherapy ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,castration‐resistant ,medicine.disease ,Diseases of the genitourinary system. Urology ,Radiation therapy ,medicine.anatomical_structure ,Radiology ,RC870-923 ,business - Abstract
Introduction The efficacy of salvage local therapy after external beam radiotherapy has recently gained attention. However, a challenge with these therapies is the risk of significant genitourinary and gastrointestinal toxicity. Focal brachytherapy may be a treatment option because of its potential to reduce side effects. Case presentation A patient with castration-resistant prostate cancer was found to be free of metastases on whole-body magnetic resonance imaging following external beam radiotherapy, and prostate biopsy revealed a localized recurrence in the ventral prostate. The patient underwent salvage focal brachytherapy and had a prostate-specific antigen progression-free survival of 23 months. No adverse effects were observed following salvage brachytherapy. Conclusion Our case suggests that salvage focal brachytherapy may be an effective local treatment option for nonmetastatic castration-resistant prostate cancer that has relapsed after external beam radiotherapy, wherein the lesion is confined to a small area within the prostate.
- Published
- 2021
18. Late recurrence of late-onset large cell calcifying Sertoli tumor successfully managed by early surgical intervention
- Author
-
Riko Ikeda, Yoh Matsuoka, Naotaka Fukui, Masaharu Inoue, Ayataka Ishikawa, and Yukio Kageyama
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
19. MP59-06 LONGITUDINAL CHANGE OF RENAL PARENCHYMAL VOLUME PRESERVED AFTER PARTIAL NEPHRECTOMY IN PATIENTS WITH PREEXISTING CHRONIC KIDNEY DISEASE
- Author
-
Minato Yokoyama, Masaki Warabino, Yosuke Yasuda, Sho Uehera, Yoh Matsuoka, Yasuhisa Fujii, Hiroshi Fukushima, Soichiro Yoshida, Shohei Fukuda, and Hajime Tanaka
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,medicine.medical_treatment ,medicine.disease ,Nephrectomy ,body regions ,Parenchyma ,Medicine ,In patient ,business ,Volume (compression) ,Kidney disease - Abstract
INTRODUCTION AND OBJECTIVE:Functional outcomes after partial nephrectomy (PN) depend on the ipsilateral (ipsi-) renal parenchymal volume (RPV) preserved. New-baseline RPV early after PN has been wi...
- Published
- 2021
- Full Text
- View/download PDF
20. MP14-11 SIGNIFICANCE OF RADIOLOGIC INFILTRATIVE FEATURE OF PRIMARY RENAL TUMOR IN PREDICTING PATIENT SURVIVAL IN METASTATIC RENAL CELL CARCINOMA
- Author
-
Yoh Matsuoka, Minato Yokoyama, Yoshitomo Yamaguchi, Hajime Tanaka, Soichiro Yoshida, Hiroshi Fukushima, Sho Uehara, Yasuhisa Fujii, Shohei Fukuda, Steven C. Campbell, and Yosuke Yasuda
- Subjects
Risk model ,medicine.medical_specialty ,business.industry ,Renal cell carcinoma ,Feature (computer vision) ,Urology ,medicine ,Patient survival ,Radiology ,Renal tumor ,urologic and male genital diseases ,business ,medicine.disease - Abstract
INTRODUCTION AND OBJECTIVE:The IMDC risk model is widely used to predict survival of patients with metastatic renal cell carcinoma (mRCC). Recent studies suggested that radiologic infiltrative feat...
- Published
- 2021
- Full Text
- View/download PDF
21. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients
- Author
-
Kazunori Kihara, Kazutaka Saito, Minato Yokoyama, Toshiki Kijima, Junichiro Ishioka, Yasuhisa Fujii, Fumitaka Koga, Soichiro Yoshida, Yoh Matsuoka, Hitoshi Masuda, and Hajime Tanaka
- Subjects
Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Cystectomy ,urologic and male genital diseases ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,medicine ,Humans ,Neoplasm Invasiveness ,Lymph node ,Aged ,Bladder cancer ,business.industry ,Chemoradiotherapy ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,Dissection ,Treatment Outcome ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Overactive bladder ,030220 oncology & carcinogenesis ,Lymph Node Excision ,Female ,International Prostate Symptom Score ,business ,Organ Sparing Treatments - Abstract
Objectives To evaluate the oncological and functional outcomes associated with selective tetramodal bladder-sparing therapy, comprising maximal transurethral resection of bladder tumour (TURBT), induction chemoradiotherapy (CRT), and consolidative partial cystectomy (PC) with pelvic lymph node dissection (PLND). Materials and methods In the present study, 154 patients with non-metastatic muscle-invasive bladder cancer (MIBC), prospectively enrolled in the tetramodal bladder-preservation protocol, were analysed. After TURBT and induction CRT, patients showing complete remission were offered consolidative PC with PLND for the achievement of bladder preservation. Pathological response to induction CRT was evaluated using PC specimens. Oncological and functional outcomes after bladder preservation were evaluated using the following endpoints: MIBC-recurrence-free survival (RFS); cancer-specific survival (CSS); overall survival (OS), and cross-sectional assessments of preserved bladder function and quality of life (QoL) including uroflowmetry, bladder diary, International Prostate Symptom Score, Overactive Bladder Symptom Score and the 36-item Short-Form Health Survey (SF-36) score. Results The median follow-up period was 48 months. Complete MIBC remission was achieved in 121 patients (79%) after CRT, and 107 patients (69%) completed the tetramodal bladder-preservation protocol comprising consolidative PC with PLND. Pathological examination in these 107 patients revealed residual invasive cancer (≥pT1) that was surgically removed in 11 patients (10%) and lymph node metastases in two patients (2%). The 5-year MIBC-RFS, CSS and OS rates in the 107 patients who completed the protocol were 97%, 93% and 91%, respectively. As for preserved bladder function, the median maximum voided volume, post-void residual urine volume, and nighttime frequency were 350 mL, 25 mL, and two voids, respectively. In the SF-36, patients had favourable scores, equivalent to the age-matched references in all the QoL scales. Conclusion Selective tetramodal bladder-preservation therapy, incorporating consolidative PC with PLND, yielded favourable oncological and functional outcomes in patients with MIBC. Consolidative PC may have contributed to the low rate of MIBC recurrence in patients treated according to this protocol.
- Published
- 2019
- Full Text
- View/download PDF
22. Infiltrative tumor interface with normal renal parenchyma in locally advanced renal cell carcinoma: Clinical relevance and pathological implications
- Author
-
Kouhei Yamamoto, Yuki Fukawa, Minato Yokoyama, Shohei Fukuda, Hajime Tanaka, Ukihide Tateishi, Yasuhisa Fujii, Soichiro Yoshida, Yoh Matsuoka, Steven C. Campbell, Hiroshi Fukushima, Sho Uehara, Koichiro Kimura, Wataru Shimada, and Yosuke Yasuda
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,medicine.medical_treatment ,medicine.disease ,Prognosis ,Nephrectomy ,Kidney Neoplasms ,Clear cell renal cell carcinoma ,Renal cell carcinoma ,Radiological weapon ,Parenchyma ,Medicine ,Humans ,Clinical significance ,Radiology ,Risk factor ,Neoplasm Recurrence, Local ,business ,Pathological ,Carcinoma, Renal Cell ,Neoplasm Staging ,Retrospective Studies - Abstract
OBJECTIVES Locally advanced renal cell carcinoma is considered clinically aggressive, despite heterogeneity in survival outcomes. We investigated the clinical relevance and pathological implications of infiltrative tumor interface with normal renal parenchyma on preoperative imaging in locally advanced renal cell carcinoma. METHODS A total of 77 patients with locally advanced renal cell carcinoma (≥pT3a Nany M0) who underwent radical or partial nephrectomy (2008-2018) were analyzed. Preoperative dynamic computed tomography images were reviewed to assess radiological infiltrative features. A radiological infiltrative feature was defined as an ill-defined tumor interface with normal renal parenchyma. The tumor interfaces were analyzed histologically and compared with radiological findings. RESULTS The median tumor size was 6.4 cm. Lymphadenopathy was observed in four patients (5.2%). Clear cell renal cell carcinoma was diagnosed in 66 patients (86%) and Fuhrman grade was 3-4 in 38 patients (49%). A total of 30 patients (39%) showed radiological infiltrative features, which were significantly associated with larger tumor size and higher clinical T stage. The specificity and sensitivity of radiological infiltrative features in predicting pathological renal parenchymal infiltration were 90 and 64%, respectively. During a median follow-up period of 3.8 years, 27 patients (35%) developed cancer recurrences, and six patients (7.8%) died of renal cell carcinoma. Multivariable analysis showed that the presence of radiological infiltrative features was an independent risk factor for cancer recurrence. Cancer recurrence and cancer-specific mortality were significantly stratified by the presence or absence of radiological infiltrative features (P
- Published
- 2021
23. Trends and safety of robot-assisted partial nephrectomy during the initial 2-year period after government approval in Japan: A nationwide database study from 2016 to 2018
- Author
-
Soichiro Yoshida, Masumi Ai, Minato Yokoyama, Hiroshi Fukushima, Kiyohide Fushimi, Yasuhisa Fujii, Junichiro Ishioka, Yoh Matsuoka, Hajime Tanaka, and Mikayo Toba
- Subjects
medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Nephrectomy ,Postoperative Complications ,Japan ,Robotic Surgical Procedures ,medicine ,Humans ,Blood Transfusion ,Stage (cooking) ,Retrospective Studies ,Government ,business.industry ,Incidence (epidemiology) ,General surgery ,Nationwide database ,Retrospective cohort study ,Robotics ,Kidney Neoplasms ,Treatment Outcome ,Propensity score matching ,Complication ,business - Abstract
Objectives To evaluate the trends and safety of robot-assisted partial nephrectomy during the initial 2-year period after government approval for this type of procedure in April 2016. Methods This nationwide retrospective study included 3722 received robot-assisted partial nephrectomy cases carried out from April 2016 to March 2018 in 124 participating institutions. The institutions were divided into lower- and higher-volume institutions according to the median of 19 robot-assisted partial nephrectomy cases during the study period. Surgical outcomes between 616 cases from lower-volume institutions and 3106 cases from higher-volume institutions were compared using propensity score matching. Results During the study period, both the number of robot-assisted partial nephrectomy surgeries and the number of institutions in which the surgery was carried out steadily increased. Overall, the median anesthesia time was 217 min, the median postoperative length of stay was 9 days, and the proportion of blood transfusions, complications and readmissions were 0.8%, 5.1% and 1.0%, respectively. There were no significant differences in anesthesia time, incidence of blood transfusions, and complication rates between the lower-volume and higher-volume institutions. However, a slightly, but significantly, longer postoperative length of stay and a lower incidence of readmission were observed in lower-volume institutions both before and after propensity score matching. Conclusions Robot-assisted partial nephrectomy has become widespread during the initial 2-year period after government approval with an acceptable safety profile, regardless of the institutional caseloads. This technique has become a standard of care for stage 1 renal cancer patients in Japan.
- Published
- 2021
24. Computer-aided Diagnosis with a Convolutional Neural Network Algorithm for Automated Detection of Urinary Tract Stones on Plain X-ray
- Author
-
Yusuke Kohno, Naoko Kawamura, Soichiro Yoshida, Minato Yokoyama, Kenji Suzuki, Rie Muta, Masaki Kobayashi, Ryota Saiki, Itsuo Kumazawa, Yasuhisa Fujii, Yuichi Fukuda, Yoh Matsuoka, Keizo Kawano, Shinji Morimoto, Junichiro Ishioka, Motohiro Fujiwara, Tetsuo Okuno, and Rumi Suda
- Subjects
Adult ,Male ,medicine.medical_specialty ,Artificial intelligence ,Adolescent ,Urology ,Datasets as Topic ,CAD ,Convolutional neural network ,Urinary tract stone ,Sensitivity and Specificity ,X-ray ,Urolithiasis ,Medicine ,Humans ,Diagnosis, Computer-Assisted ,Upper urinary tract ,Aged ,Aged, 80 and over ,business.industry ,Deep learning ,Research ,Urinary tract stones ,General Medicine ,Middle Aged ,Diseases of the genitourinary system. Urology ,Radiography ,Reproductive Medicine ,Computer-aided diagnosis ,Radiographic Image Interpretation, Computer-Assisted ,Female ,Urinary Calculi ,Radiology ,RC870-923 ,Neural Networks, Computer ,F1 score ,business ,Test data - Abstract
Background Recent increased use of medical images induces further burden of their interpretation for physicians. A plain X-ray is a low-cost examination that has low-dose radiation exposure and high availability, although diagnosing urolithiasis using this method is not always easy. Since the advent of a convolutional neural network via deep learning in the 2000s, computer-aided diagnosis (CAD) has had a great impact on automatic image analysis in the urological field. The objective of our study was to develop a CAD system with deep learning architecture to detect urinary tract stones on a plain X-ray and to evaluate the model’s accuracy. Methods We collected plain X-ray images of 1017 patients with a radio-opaque upper urinary tract stone. X-ray images (n = 827 and 190) were used as the training and test data, respectively. We used a 17-layer Residual Network as a convolutional neural network architecture for patch-wise training. The training data were repeatedly used until the best model accuracy was achieved within 300 runs. The F score, which is a harmonic mean of the sensitivity and positive predictive value (PPV) and represents the balance of the accuracy, was measured to evaluate the model’s accuracy. Results Using deep learning, we developed a CAD model that needed 110 ms to provide an answer for each X-ray image. The best F score was 0.752, and the sensitivity and PPV were 0.872 and 0.662, respectively. When limited to a proximal ureter stone, the sensitivity and PPV were 0.925 and 0.876, respectively, and they were the lowest at mid-ureter. Conclusion CAD of a plain X-ray may be a promising method to detect radio-opaque urinary tract stones with satisfactory sensitivity although the PPV could still be improved. The CAD model detects urinary tract stones quickly and automatically and has the potential to become a helpful screening modality especially for primary care physicians for diagnosing urolithiasis. Further study using a higher volume of data would improve the diagnostic performance of CAD models to detect urinary tract stones on a plain X-ray.
- Published
- 2021
- Full Text
- View/download PDF
25. Nonuse of antimicrobial prophylaxis in clean surgeries for adrenal and renal tumors: Results of the risk-based strategy in 1362 consecutive patients
- Author
-
Kazutaka Saito, Kazunori Kihara, Toshiki Kijima, Shohei Fukuda, Yoh Matsuoka, Hajime Tanaka, Minato Yokoyama, Yosuke Yasuda, Yasuhisa Fujii, Riko Maruyama, Hiroshi Fukushima, Sho Uehara, and Soichiro Yoshida
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,medicine.medical_treatment ,Urinary system ,Adrenalectomy ,Incidence (epidemiology) ,Perioperative ,Antibiotic Prophylaxis ,Antimicrobial ,Individual risk ,Nephrectomy ,Kidney Neoplasms ,Surgery ,Anti-Bacterial Agents ,medicine ,Humans ,Surgical Wound Infection ,Antibiotic prophylaxis ,business ,Retrospective Studies - Abstract
OBJECTIVES To evaluate the incidence of perioperative infections without antimicrobial prophylaxis in patients undergoing clean surgeries for adrenal and renal tumors. METHODS We prospectively enrolled 1362 consecutive patients who underwent minimally invasive adrenalectomy (n = 303), radical nephrectomy (n = 499), and partial nephrectomy (n = 560) using the gasless laparoendoscopic single-port surgery technique between 2005 and 2019. In 1059 patients, antimicrobial prophylaxis was not administered. The remaining 303 patients were considered at high risk for infection and received single-dose antimicrobial prophylaxis. The endpoint was the incidence of perioperative infections within 1 month from the surgery date. Perioperative infections were classified into surgical site infections, urinary tract infections, and remote infections. RESULTS Seventy-four patients whose collecting systems were opened during partial nephrectomy were excluded, and the remaining 1013 patients with nonuse of antimicrobial prophylaxis and 275 patients with single-dose antimicrobial prophylaxis were retrospectively analyzed. The incidence of superficial surgical site infections, deep/organ-space surgical site infections, urinary tract infections, and remote infections was 1.6%, 0.7%, 2.8%, and 1.3%, respectively, in patients with nonuse of antimicrobial prophylaxis and 0.4%, 1.8%, 1.5%, and 1.5%, respectively, in patients with single-dose antimicrobial prophylaxis. All patients who developed perioperative infections were successfully treated. No clinical or surgical variables were significantly associated with the incidence of surgical site infections. One limitation of the present study was its nonrandomized and noncontrolled design. CONCLUSIONS In minimally invasive clean surgeries for adrenal and renal tumors, antimicrobial prophylaxis is not necessary when individual risk of infection is considered low.
- Published
- 2021
26. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus
- Author
-
Wei Phin Tan, Ardeshir R. Rastinehad, Laurence Klotz, Peter R. Carroll, Mark Emberton, John F. Feller, Arvin K. George, Inderbir S. Gill, Rajan T. Gupta, Aaron E. Katz, Amir H. Lebastchi, Leonard S. Marks, Giancarlo Marra, Peter A. Pinto, Daniel Y. Song, Abhinav Sidana, John F. Ward, Rafael Sanchez-Salas, Jean de la Rosette, Thomas J Polascik, Aaron Katz, Alireza Aminsharifi, Amir Lebastchi, Andre Abreu, Arnauld Villers, Ariel Schulman, Ardeshir Rastinehad, Arvin George, Aytekin Oto, Baris Turkbey, Bernard Malavaud, Berrend Muller, Caroline Moore, Daniel Eberli, Daniel Margolis, Daniel Song, Derek Lomas, Hazem Orabi, Herbert Lepor, Hui Meng Tan, Ivan Jambor, Jeremy Grummet, John Feller, John Ward, Jonathan Colemen, Justin Gregg, Kae Jack Tay, Leonard Marks, Leslie Deane, M. Pilar Laguna, Masaki Kimura, Matvey Tsivian, Michael Gorin, Minhaj Siddiqui, Osamu Ukimura, Paolo Gontero, Peter Carroll, Peter Pinto, Pierre Mozer, Rajan T Gupta, Ro Arcot, Samir Taneja, Sangeet Ghai, Sebastian Crouzet, Sherif Mehralivand, Steven Joniau, Sunao Shoji, Takumi Shiraishi, Thomas Polascik, Toshitaka Shin, Uri Lindnet, Varaha Tammisetti, Willemien van den Bos, Yoh Matsuoka, University of Zurich, and Polascik, Thomas J
- Subjects
Ablation Techniques ,Male ,Delphi Technique ,030232 urology & nephrology ,Active surveillance ,Prostate cancer ,0302 clinical medicine ,80 and over ,computer.programming_language ,Cancer ,Aged, 80 and over ,Prostate Cancer ,Urology & Nephrology ,Middle Aged ,Oncology ,030220 oncology & carcinogenesis ,Respondent ,2730 Oncology ,2748 Urology ,Urologic Diseases ,medicine.medical_specialty ,Consensus ,Urology ,Oncology and Carcinogenesis ,Partial gland ablation ,Active surveillance of prostate cancer ,610 Medicine & health ,Article ,Focal Therapy Group Authors ,03 medical and health sciences ,Clinical Research ,Focal therapy ,Radiation oncology ,medicine ,Humans ,Radical therapy ,Watchful Waiting ,Aged ,Localized prostate cancer ,business.industry ,Prostatic Neoplasms ,medicine.disease ,10062 Urological Clinic ,Family medicine ,Imaging technology ,business ,computer ,Delphi - Abstract
Background: With the advancement of imaging technology, focal therapy (FT) has been gaining acceptance for the treatment of select patients with localized prostate cancer (CaP). We aim to provide details of a formal physician consensus on the utilization of FT for patients with CaP who are discontinuing active surveillance (AS). Methods: A 3-stage Delphi consensus on CaP and FT was conducted. Consensus was defined as agreement by >= 80% of physicians. An in-person meeting was attended by 17 panelists to formulate the consensus statement. Results: Fifty-six respondents participated in this interdisciplinary consensus study (82% urologist, 16% radiologist, 2% radiation oncology). The participants confirmed that there is a role for FT in men discontinuing AS (48% strongly agree, 39% agree). The benefit of FT over radical therapy for men coming off AS is: less invasive (91%), has a greater likelihood to preserve erectile function (91%), has a greater likelihood to preserve urinary continence (91%), has fewer side effects (86%), and has early recovery post-treatment (80%). Patients will need to undergo mpMRI of the prostate and/or a saturation biopsy to determine if they are potential candidates for FT. Our limitations include respondent's biases and that the participants of this consensus may not represent the larger medical community. Conclusions: FT can be offered to men coming off AS between the age of 60 to 80 with grade group 2 localized cancer. This consensus from a multidisciplinary, multi-institutional, international expert panel provides a contemporary insight utilizing FT for CaP in select patients who are discontinuing AS. United States Department of Health & Human Services National Institutes of Health (NIH) - USA ; European Urological Scholarship Programme (EUSP)
- Published
- 2021
27. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy
- Author
-
Yoh Matsuoka, Sho Uehara, Kazuma Toda, Hiroshi Fukushima, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Ryoichi Yoshimura, Kazunori Kihara, and Yasuhisa Fujii
- Subjects
Male ,Prostatectomy ,Salvage Therapy ,Treatment Outcome ,Oncology ,Urology ,Brachytherapy ,Humans ,Prostatic Neoplasms ,Prostate-Specific Antigen ,Retrospective Studies - Abstract
To report experience with focal brachytherapy (FB) and compare its clinical outcomes with those of radical prostatectomy (RP) in localized prostate cancer.Fifty-one patients with low- to intermediate-risk prostate cancer underwent low-dose-rate FB. Survival rates free from biochemical failure (BF), additional treatment (AT) including re-FB, and whole-gland or systemic salvage therapy (ST) were calculated and oncological risk factors were investigated. Patient-reported outcomes on genitourinary function were also assessed. Using propensity scoring, 51 pair-matched RP patients were selected. Oncological control, urinary continence, and ejaculation status after FB and RP were compared.During a median 5.7-year follow-up, BF, AT, and ST occurred in 12 (24%), 10 (20%), and 4 FB patients (8%), respectively. 6 of 10 AT patients were managed with re-FB alone. In the RP cohort, 3 patients (6%) underwent ST. 5-year BF-free survival rate after FB was 79%. Compared to 5-year ST-free survival rate of 94% after RP, ST-free and AT-free survival rates after FB were 93% (P = 0.813) and 87% (P = 0.049), respectively. Multivariate analyses of FB-treated patients showed that time to PSA nadir was negatively associated with BF and AT (hazard ratio 0.84 and 0.83, respectively, P0.001 for each). The difference in oncological outcomes between low- and intermediate-risk categories was not significant. At 2 years after FB and RP, pad-free continence rates were 100% and 81%, respectively (P = 0.001). Ejaculation was preserved in 67% and 0% of patients who had been capable of ejaculation at baseline, respectively (P0.001).In low- to intermediate-risk prostate cancer, FB-treated patients achieved superior genitourinary function compared to pair-matched RP patients. The need for ST was not substantially different between the 2 treatment cohorts. Over half of patients requiring AT could be managed by re-focal treatment rather than whole-gland ST. Early PSA nadir may predict poor oncological control after FB.
- Published
- 2022
- Full Text
- View/download PDF
28. Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer
- Author
-
Soichiro Yoshida, Kazuma Toda, Yasuhisa Fujii, Ryoichi Yoshimura, Kazutaka Saito, Minato Yokoyama, Yoh Matsuoka, and Kazunori Kihara
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Brachytherapy ,Urology ,030218 nuclear medicine & medical imaging ,Metastasis ,Iodine Radioisotopes ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Biopsy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,medicine.diagnostic_test ,business.industry ,Cancer ,Prostatic Neoplasms ,Prostate-Specific Antigen ,medicine.disease ,Low-Dose Rate Brachytherapy ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,International Prostate Symptom Score ,Sexual function ,business ,Follow-Up Studies - Abstract
PURPOSE To examine medium-term outcomes of hemi-gland low-dose-rate brachytherapy as a primary treatment for intermediate-risk prostate cancer. METHODS We recruited intermediate-risk unilateral prostate cancer patients for a prospective trial of hemi-gland brachytherapy. Twenty-four patients underwent hemi-gland iodine-125 seed implantation with a prescribed dose of 160 Gy. Serum prostate-specific antigen (PSA) was measured regularly and follow-up biopsy was scheduled after 2–3 years of treatment. When clinically needed afterward, for-cause biopsy was performed to confirm pathology. Treatment failure (TF)-free survival, which was defined as freedom from radical or systemic therapy, metastases, and cancer-specific mortality, was assessed, as was biochemical failure (BF)-free survival. Urinary and sexual functions were also evaluated. RESULTS Median follow-up duration was 61 months. Twenty-two patients (92%) exhibited a declining trend or decreased value of PSA for 12 months or longer after the treatment. Follow-up biopsy in the initial triennium and for-cause biopsy in the subsequent triennium were performed in 16 and four patients, respectively, and cancer was found from the treated lobe in one patient (4% of the cohort) and significant cancer was found from untreated lobes in four patients (17%) in total. Secondary treatments were performed in six patients successfully. Five-year freedom from BF, TF, and metastasis was 71%, 90%, and 100%, respectively. The International Prostate Symptom Score significantly deteriorated at 3 months and reversed itself afterward. The International Index of Erectile Function 5 had no significant decrease. CONCLUSIONS Hemi-gland low-dose-rate brachytherapy provides favorable medium-term oncological outcomes with genito-urinary functional preservation for men with intermediate-risk unilateral prostate cancer.
- Published
- 2020
29. Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy
- Author
-
Yuki Arita, Ichiro Yamada, Ryoichi Yoshimura, Soichiro Yoshida, Yasuhisa Fujii, Yoh Matsuoka, Hajime Tanaka, Minato Yokoyama, Taro Takahara, and Kazuma Toda
- Subjects
Nephrology ,Oncology ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Disease ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,Systemic therapy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,Neoplasm Metastasis ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,Taxane ,Radiotherapy ,business.industry ,Therapeutic effect ,medicine.disease ,Radiation therapy ,Prostatic Neoplasms, Castration-Resistant ,Diffusion Magnetic Resonance Imaging ,business - Abstract
To evaluate the clinical characteristics of genuine- and induced-oligometastatic castration-resistant prostate cancer (OM-CRPC) and assess the therapeutic effect of progressive-site directed therapy (PSDT). We performed a retrospective analysis of 45 patients with OM-CRPC. Whole-body diffusion-weighted MRI (WB-DWI) was used to diagnose oligo-progressive disease. Based on the clinical and radiological findings, the OM-CRPCs were classified as genuine or induced. PSDT was performed with the intent to ablate all the progressive sites detected on WB-DWI with radiotherapy. Systemic therapy remained unchanged during and after PSDT. A total of 31 (69%) and 14 (31%) patients were diagnosed with genuine- and induced-OM-CRPC, respectively. The genuine-OM-CRPC group had significantly fewer patients treated with taxane-based chemotherapy and new hormonal drugs than the induced-OM-CRPC group. Of these, 26 OM-CRPC patients were treated with PSDT, and a 50% PSA decline was observed in 14 (93%) of 15 patients with genuine-OM-CRPC and 4 (36%) of 11 patients with induced-OM-CRPC (P = 0.033). Further, the duration of PSA-progression-free survival was significantly longer in the genuine-OM-CRPC group than in the induced-OM-CRPC group (8.7 vs. 5.8 months, P = 0.040). PSDT can be a promising treatment option for genuine-OM-CRPC. The procedure might also be considered effective for induced-OM-CRPC, although there was less therapeutic benefit of PSDT in patients with induced-OM-CRPC than in patients with genuine-OM-CRPC.
- Published
- 2020
30. Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems
- Author
-
Soichiro Yoshida, Minato Yokoyama, Sho Uehara, Yasuhisa Fujii, Hajime Tanaka, and Yoh Matsuoka
- Subjects
Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Magnetic Resonance Spectroscopy ,medicine.diagnostic_test ,business.industry ,Urology ,Biopsy ,Prostatic Neoplasms ,Magnetic resonance imaging ,medicine.disease ,Targeted biopsy ,Magnetic Resonance Imaging ,Prostate cancer ,Margin (machine learning) ,medicine ,Humans ,Sampling (medicine) ,Radiology ,Neoplasm Grading ,business ,Systematic biopsy ,Ultrasonography, Interventional - Published
- 2020
31. Long-term survival after radical cystectomy and mesenteric lymph node dissection for squamous cell carcinoma arising from augmented bladder with lymph node metastasis: a case report
- Author
-
Minato Yokoyama, Hajime Tanaka, Soichiro Yoshida, Susumu Kirimura, Yasuhisa Fujii, Takahiko Soma, Yusuke Uchida, and Yoh Matsuoka
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Urology ,Cancer ,Case Report ,Lymph node metastasis ,medicine.disease ,urologic and male genital diseases ,Cystectomy ,Dissection ,medicine.anatomical_structure ,Surgical oncology ,medicine ,Basal cell ,business ,Lymph node ,Augmented bladder - Abstract
Surgical resection is commonly performed for augmented bladder cancer, yet an optimal treatment strategy for augmented bladder cancer with lymph node metastasis has not been established. Here, we report a case that achieved 7 years of survival after radical cystectomy and mesenteric lymph node dissection for squamous cell carcinoma arising from augmented bladder with lymph node metastasis. Extended surgery could be a useful treatment option for locally advanced augmented bladder cancer including mesenteric lymph node metastasis.
- Published
- 2020
32. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review
- Author
-
Nobuaki Matsubara, Junji Yonese, Minato Yokoyama, Hitoshi Masuda, Kazutaka Saito, Yasuhisa Fujii, Shota Kusuhara, Soichiro Yoshida, Yukio Kageyama, Yasuyuki Sakai, Toshiki Kijima, Takeshi Yuasa, Hajime Tanaka, Noboru Numao, Junichiro Ishioka, Hiroshi Fukushima, and Yoh Matsuoka
- Subjects
Oncology ,medicine.medical_specialty ,Urology ,030232 urology & nephrology ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Internal medicine ,Neoplasms ,Medicine ,Urothelial cancer ,Humans ,Multicenter Studies as Topic ,Progression-free survival ,Adverse effect ,Immune Checkpoint Inhibitors ,Retrospective Studies ,business.industry ,Common Terminology Criteria for Adverse Events ,Systematic review ,030220 oncology & carcinogenesis ,Cohort ,business - Abstract
An association between the development of overall or specific immune-related adverse events (irAEs) and outcomes of immune checkpoint inhibitors has recently been suggested. To address this emerging association in patients with urothelial cancer receiving pembrolizumab, we conducted a multicenter retrospective analysis, which is the first and largest in an Asian cohort as well as a systematic literature review. We retrospectively evaluated 97 patients with advanced urothelial cancer treated with pembrolizumab as second- or later-line treatment between January 2018 and March 2019. irAEs were categorized by the involved organs and graded using Common Terminology Criteria for Adverse Events version 5.0. Associations between irAEs and pembrolizumab efficacy, including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), were evaluated. In our review of the literature, 28 studies, including 9 studies involving patients with urothelial cancer and 19 studies reporting the association between outcomes and spectrum of irAEs, were analyzed. Patients with irAEs had significantly higher ORR (52% vs. 16%, P .01), longer PFS (11.0 months vs. 3.6 months, P .01) and OS (median not reached vs. 13.1 months, P = .12) than in patients without irAEs. Endocrine (P = .02), pneumological (P = .06), and other (gastrointestinal, hematological, hepatic) (P = .04) irAEs were associated with increased ORR, whereas skin irAEs were not. Endocrine irAEs (P = .04) was associated with improved OS, whereas pneumological and skin irAEs were not. The association between the occurrence of irAEs and clinical efficacy of immune checkpoint inhibitors was consistently supported by the multiple studies we reviewed. The association between clinical outcomes and the spectrum of organs/systems affected by irAEs seems to be inconsistent and could be dependent on tumor type. irAEs were associated with a higher ORR and better survival of patients with advanced urothelial cancer treated with pembrolizumab.
- Published
- 2020
33. MP34-10 THE UTILITY OF MIXED REALITY MODEL PROJECTION IN ULTRASOUND TRAINING FOR MEDICAL STUDENTS
- Author
-
Shingo Moriyama, Sho Uehara, Minato Yokoyama, Maki Sugimoto, Yasuhisa Fujii, Soichiro Yoshida, Toshiki Kijima, Jyunichirou Ishioka, Hajime Tanaka, Yoh Matsuoka, Kazutaka Saito, Naoji Taniguchi, and Takeki Ito
- Subjects
business.industry ,Urology ,Ultrasound ,Medical imaging ,Wearable computer ,Medicine ,Computer vision ,Artificial intelligence ,business ,Projection (set theory) ,Mixed reality - Abstract
INTRODUCTION AND OBJECTIVE:Mixed reality (MR) is a novel tool that is expected to assist medical imaging. A wearable MR device allows its wearer to view holographic 3-dimensional (3D) images projec...
- Published
- 2020
- Full Text
- View/download PDF
34. MP42-13 APPARENT DIFFUSION COEFFICIENT RATIO AS A QUANTITATIVE IMAGING MARKER: UTILITY IN A NOMOGRAM FOR PREDICTING BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
- Author
-
Kazutaka Saito, Toshiki Kijima, Sho Uehara, Shingo Moriyama, Hajime Tanaka, Hiroshi Fukushima, Soichiro Yoshida, Junichiro Ishioka, Shohei Fukuda, Yoh Matsuoka, Hiroshi Tanaka, Minato Yokoyama, and Yasuhisa Fujii
- Subjects
Biochemical recurrence ,medicine.medical_specialty ,Quantitative imaging ,Prostatectomy ,business.industry ,Urology ,medicine.medical_treatment ,Nomogram ,medicine.disease ,Prostate cancer ,medicine ,Effective diffusion coefficient ,business ,Value (mathematics) - Abstract
INTRODUCTION AND OBJECTIVE:Image quantitation facilitates its integration with other data. However, apparent diffusion coefficient value (ADCV) of prostate cancer (PC) is of limited usefulness beca...
- Published
- 2020
- Full Text
- View/download PDF
35. MP46-10 THE QSOFA SCORE OUTPERFORMS THE SIRS SCORE IN PREDICTING IN-HOSPITAL MORTALITY OF OBSTRUCTIVE PYELONEPHRITIS PATIENTS: RESULTS FROM A MULTI-INSTITUTIONAL STUDY
- Author
-
Fumitaka Koga, Toshihiko Tsujii, Tetsuo Okuno, Katsushi Nagahama, Shinji Morimoto, Junji Yonese, Yasuhisa Fujii, Toshiki Kijima, Yoh Matsuoka, Tetsuro Tsukamoto, Yukio Kageyama, Shigeyoshi Kamata, Kazutaka Saito, Minato Yokoyama, Akira Noro, Yukihiro Otsuka, Hitoshi Masuda, Masataka Yano, Rie Kato, Junichiro Ishioka, Hiroshi Fukushima, and Soichiro Yoshida
- Subjects
medicine.medical_specialty ,In hospital mortality ,business.industry ,Urology ,Internal medicine ,medicine ,Obstructive pyelonephritis ,business - Published
- 2020
- Full Text
- View/download PDF
36. PD44-04 RELATIONSHIP BETWEEN NOCTURIA AND WHOLE-BODY FLUID DISTRIBUTION ASSESSED BY BIOELECTRICAL IMPEDANCE
- Author
-
Hiroshi Fukushima, Shohei Fukuda, Shingo Moriyama, Sho Uehara, Hajime Tanaka, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Yasuko Abe, Yousuke Takemura, and Yasuhisa Fujii Tokyo, Japan
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,fungi ,food and beverages ,urologic and male genital diseases ,female genital diseases and pregnancy complications ,Quality of life ,Physical therapy ,Medicine ,Nocturia ,Distribution (pharmacology) ,medicine.symptom ,Whole body ,business ,Bioelectrical impedance analysis - Abstract
INTRODUCTION AND OBJECTIVE:Nocturia, which not only lowers quality of life but also increases all-cause mortality, is one of the most distressing symptoms in elderly populations. Nocturia can be ca...
- Published
- 2020
- Full Text
- View/download PDF
37. MP40-15 LONGITUDINAL CHANGE IN URINARY INCONTINENCE, LOWER URINARY TRACT SYMPTOMS AND QUALITY OF LIFE AFTER ARTIFICIAL URINARY SPHINCTER IMPLANTATION
- Author
-
Minato Yokoyama, Masahiro Toide, Yuma Waseda, Junichiro Ishioka, Yasuhisa Fujii, Sho Uehara, Toshiki Kijima, Yoh Matsuoka, Kazutaka Saito, Masaya Ito, Shingo Moriyama, Soichiro Yoshida, Hitoshi Masuda, Yusuke Uchida, and Hajime Tanaka
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,Standard treatment ,digestive, oral, and skin physiology ,food and beverages ,Urinary incontinence ,medicine.disease ,digestive system ,Artificial urinary sphincter ,Quality of life ,Lower urinary tract symptoms ,otorhinolaryngologic diseases ,medicine ,medicine.symptom ,business - Abstract
INTRODUCTION AND OBJECTIVE:Artificial urinary sphincter (AUS) implantation is the standard treatment for severe male sphincteric urinary incontinence (UI). Although AUS can remarkably improve vario...
- Published
- 2020
- Full Text
- View/download PDF
38. PD16-03 TREATMENT-INDUCED CHANGES OF BRAIN NATRIURETIC PEPTIDE (BNP) LEVELS IN PROSTATE CANCER PATIENTS RECEIVING GNRH ANTAGONISTS OR AGONISTS
- Author
-
Minato Yokoyama, Kazutaka Saito, Yasuhisa Fujii, Junichiro Ishioka, Soichiro Yoshida, Toshiki Kijima, Hajime Tanaka, Shohei Fukuda, Hiroshi Fukushima, Sho Uehara, Masaya Ito, Shingo Moriyama, and Yoh Matsuoka
- Subjects
Androgen deprivation therapy ,medicine.medical_specialty ,Prostate cancer ,Endocrinology ,business.industry ,Urology ,Internal medicine ,Medicine ,Disease ,business ,medicine.disease ,Brain natriuretic peptide - Abstract
INTRODUCTION AND OBJECTIVE:Previous studies revealed that androgen deprivation therapy (ADT) may increase the risk of cardiovascular disease (CVD). Limited data suggested that GnRH antagonists were...
- Published
- 2020
- Full Text
- View/download PDF
39. MP46-15 LOW INCIDENCE OF PERIOPERATIVE INFECTIONS WITHOUT ANTIMICROBIAL PROPHYLAXIS IN CLEAN SURGERIES FOR ADRENAL AND RENAL TUMORS: A PROSPECTIVE SINGLE-INSTITUTIONAL STUDY OF 1339 PATIENTS
- Author
-
Soichiro Yoshida, Yasuhisa Fujii, Hajime Tanaka, Hiroshi Fukushima, Riko Maruyama, Toshiki Kijima, Yoh Matsuoka, Junichiro Ishioka, Shohei Fukuda, Shingo Moriyama, Minato Yokoyama, Sho Uehara, and Kazutaka Saito
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,Incidence (epidemiology) ,Internal medicine ,medicine ,Perioperative ,Antimicrobial ,business - Abstract
INTRODUCTION AND OBJECTIVE:There is little scientific evidence regarding the use of antimicrobial prophylaxis (AMP) in clean urologic surgeries for adrenal and renal tumors. According to the AUA gu...
- Published
- 2020
- Full Text
- View/download PDF
40. MP42-16 SYSTEMATIC BIOPSY CORES AWAY FROM TARGETS ARE OF LIMITED VALUE FOR THE DETECTION OF SIGNIFICANT CANCER: ANALYSIS OF 3D PROSTATE BIOPSY MAPPING USING MULTIPLANAR MRI RECONSTRUCTION
- Author
-
Soichiro Yoshida, Hajime Tanaka, Kazutaka Saito, Yasuhisa Fujii, Toshiki Kijima, Sho Uehara, Shingo Moriyama, Junichiro Ishioka, Minato Yokoyama, Hitoshi Tanaka, and Yoh Matsuoka
- Subjects
medicine.medical_specialty ,Prostate biopsy ,medicine.diagnostic_test ,business.industry ,Urology ,medicine ,Cancer ,Radiology ,medicine.disease ,business ,Value (mathematics) ,Systematic biopsy - Published
- 2020
- Full Text
- View/download PDF
41. MP49-09 CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS SPECTRUM AND PROGNOSIS IN PATIENTS WITH ADVANCED UROTHELIAL CANCER TREATED WITH PEMBROLIZUMAB
- Author
-
Nobuaki Matsubara, Hajime Tanaka, Hithoshi Masuda, Junichiro Ishioka, Yukio Kageyama, Kazutaka Saito, Takeshi Yuasa, Yasuhisa Fujii, Yasuyuki Sakai, Toshiki Kijima, Takashi Tamiya, Noboru Numao, Junji Yonese, Soichiro Yoshida, and Yoh Matsuoka
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,animal diseases ,Urology ,Immune checkpoint inhibitors ,chemical and pharmacologic phenomena ,Pembrolizumab ,biochemical phenomena, metabolism, and nutrition ,Immune system ,Internal medicine ,medicine ,bacteria ,Urothelial cancer ,In patient ,business ,Adverse effect - Abstract
INTRODUCTION AND OBJECTIVE:Recent studies have suggested that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors were associated with clinical benefit, and its predictive ...
- Published
- 2020
- Full Text
- View/download PDF
42. MP37-13 TREATMENT OUTCOMES OF PROGRESSIVE SITE-DIRECTED THERAPY FOR OLIGO-PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER
- Author
-
Kazuma Toda, Yasuhisa Fujii, Minato Yokoyama, Ryoichi Yoshimura, Soichiro Yoshida, Taro Takahara, Kazutaka Saito, Yuki Arita, Chikako Ishii, Tsuyoshi Sakamoto, Junichiro Ishioka, Toshiki Kijima, and Yoh Matsuoka
- Subjects
Oncology ,medicine.medical_specialty ,Prostate cancer ,business.industry ,Urology ,Internal medicine ,Treatment outcome ,medicine ,Castration resistant ,medicine.disease ,business - Published
- 2020
- Full Text
- View/download PDF
43. MP36-08 QUANTITATIVE ASSESSMENT OF WHOLE-BODY DIFFUSION-WEIGHTED MRI AS A PROGNOSTIC IMAGING BIOMARKER OF METASTATIC UROTHELIAL CANCER
- Author
-
Yasuhisa Fujii, Toshiki Kijima, Tsuyoshi Sakamoto, Sao Katsumura, Minato Yokoyama, Taro Takahara, Kazutaka Saito, Hajime Tanaka, Yusuke Uchida, Yoh Matsuoka, Soichiro Yoshida, Hiroshi Fukushima, Junichiro Ishioka, and Sho Uehara
- Subjects
medicine.medical_specialty ,Imaging biomarker ,business.industry ,Urology ,Quantitative assessment ,Urothelial cancer ,Medicine ,Radiology ,business ,Whole body ,Diffusion MRI - Published
- 2020
- Full Text
- View/download PDF
44. Application of virtual reality in patient explanation of magnetic resonance imaging-ultrasound fusion prostate biopsy
- Author
-
Soichiro Yoshida, Kazutaka Saito, Yoh Matsuoka, Shingo Moriyama, Naoji Taniguchi, and Yasuhisa Fujii
- Subjects
Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Prostate biopsy ,medicine.diagnostic_test ,business.industry ,Urology ,Ultrasound ,Prostate ,Virtual Reality ,Prostatic Neoplasms ,Magnetic resonance imaging ,Virtual reality ,Magnetic Resonance Imaging, Interventional ,Magnetic Resonance Imaging ,Medicine ,Humans ,In patient ,Radiology ,Ultrasonography ,business ,Ultrasonography, Interventional - Published
- 2020
45. Value of extra-target prostate biopsy for the detection of magnetic resonance imaging-missed adverse pathology according to the Prostate Imaging Reporting and Data System scores: Spatial analysis using magnetic resonance-ultrasound fusion images
- Author
-
Kazutaka Saito, Yasuhisa Fujii, Toshiki Kijima, Hiroshi Tanaka, Minato Yokoyama, Hajime Tanaka, Soichiro Yoshida, Yoh Matsuoka, Sho Uehara, and Junichiro Ishioka
- Subjects
Image-Guided Biopsy ,Male ,Pathology ,medicine.medical_specialty ,Prostate biopsy ,Magnetic Resonance Spectroscopy ,Urology ,030232 urology & nephrology ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Biopsy ,medicine ,Humans ,Sampling (medicine) ,Ultrasonography, Interventional ,Spatial Analysis ,medicine.diagnostic_test ,business.industry ,Cancer ,Prostatic Neoplasms ,Magnetic resonance imaging ,Odds ratio ,medicine.disease ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Neoplasm Grading ,business - Abstract
OBJECTIVES To clarify who benefits from extra-target sampling of systematic prostate biopsy to detect magnetic resonance imaging-missed significant cancer and upgrading, when concurrently carried out with magnetic resonance imaging-ultrasound fusion targeted biopsy. METHODS Targeted biopsy and systematic biopsy were carried out in 301 men with Prostate Imaging Reporting and Data System scores ≥3. All score ≥3 regions were designated as targets. According to patients' highest Prostate Imaging Reporting and Data System scores, spatial relations between targets and biopsy-proven cancer were investigated to identify magnetic resonance imaging-missed pathology. RESULTS Overall, targeted biopsy and systematic biopsy detected significant cancer in 56.5% and 46.5%, respectively (P
- Published
- 2020
46. Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists
- Author
-
Toshiki Kijima, Masaya Ito, Junichiro Ishioka, Yoh Matsuoka, Yasuhisa Fujii, and Kazutaka Saito
- Subjects
Male ,Thesaurus (information retrieval) ,business.industry ,Urology ,Prostatic Neoplasms ,Androgen Antagonists ,Gonadotropin-releasing hormone ,Pharmacology ,Brain natriuretic peptide ,medicine.disease ,Gonadotropin-Releasing Hormone ,Prostate cancer ,Natriuretic Peptide, Brain ,medicine ,Humans ,business - Published
- 2020
47. Predictive ability of renal cortex enhancement in dynamic computed tomography for residual renal function after nephroureterectomy: Comparison with 99m Tc‐diethylenetriaminopentacetic acid renography and validation study
- Author
-
Kazunori Kihara, Kazutaka Saito, Shinji Morimoto, Yuma Waseda, Yudai Ishikawa, Keizo Kawano, Junichiro Ishioka, Yoh Matsuoka, Minato Yokoyama, and Yasuhisa Fujii
- Subjects
Kidney ,business.industry ,Urology ,Radiodensity ,Renal cortex ,030232 urology & nephrology ,Renal function ,Combination chemotherapy ,Perioperative ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Transitional cell carcinoma ,030220 oncology & carcinogenesis ,Hounsfield scale ,Medicine ,business ,Nuclear medicine - Abstract
Objective To estimate postoperative residual renal function after radical nephroureterectomy for upper tract urothelial carcinoma using the preoperative dynamic computed tomography renal cortex enhancement ratio in comparison with the split kidney glomerular filtration rate measured by 99m Tc-diethylenetriaminopentacetic acid renography. Methods A total of 47 patients who received radical nephroureterectomy and underwent both preoperative dynamic computed tomography and renography were the model-development cohort; and 109 patients who underwent dynamic computed tomography alone were the validation cohort. Postoperative renal function of the unremoved kidney was estimated using the following formulas: preoperative estimated glomerular filtration rate × the percentage of total renal cortex radiodensity for the intact kidney in Hounsfield units obtained from corticomedullary phase images in the computed tomography-based model, or the percentage of the total glomerular filtration rate measured by renography in the nuclear model. The correlation between observed and estimated postoperative renal function was determined. The computed tomography-based prediction model derived from linear regression analysis was validated externally. Results The correlation of computed tomography-based split renal function with the observed postoperative estimated glomerular filtration rate (r = 0.80) was equivalent to that of nuclear split renal function (r = 0.78). In the validation cohort, the computed tomography-based prediction model showed an equivalently strong correlation (r = 0.78). Conclusions The present study showed that the percentage of total renal cortex radiodensity for the intact kidney is a useful tool for predicting unremoved kidney function in upper tract urothelial carcinoma patients, thereby allowing appropriate patient selection for perioperative cisplatin-based combination chemotherapy.
- Published
- 2018
- Full Text
- View/download PDF
48. Acute kidney injury and intermediate-term renal function after clampless partial nephrectomy
- Author
-
Takayuki Nakayama, Naoko Kawamura, Kazutaka Saito, Yoh Matsuoka, Hajime Tanaka, Toshiki Kijima, Soichiro Yoshida, Kazunori Kihara, Junichiro Ishioka, Yasuhisa Fujii, Minato Yokoyama, and Yosuke Yasuda
- Subjects
Adult ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Renal function ,Logistic regression ,Nephrectomy ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Renal cell carcinoma ,Diabetes mellitus ,Humans ,Medicine ,Warm Ischemia ,Aged ,Aged, 80 and over ,urogenital system ,business.industry ,Incidence (epidemiology) ,Acute kidney injury ,Perioperative ,Acute Kidney Injury ,Middle Aged ,medicine.disease ,Survival Analysis ,Treatment Outcome ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Female ,business ,Glomerular Filtration Rate - Abstract
Objectives To evaluate the incidence and predictors of acute kidney injury after clampless partial nephrectomy, and its impact on intermediate-term renal function. Methods The incidence and severity of acute kidney injury were assessed for 262 patients undergoing clampless partial nephrectomy between 2010 and 2015. The association between perioperative covariates and acute kidney injury was evaluated using multivariate logistic regression analysis. An annual change in estimated glomerular filtration rate from 1 year after surgery was calculated according to the presence or absence of acute kidney injury. An impact of acute kidney injury on postoperative renal impairment, defined as a ≥25% estimated glomerular filtration rate decrease, was evaluated. Results Overall, 21 (8.0%) patients experienced grade 1 acute kidney injury after clampless partial nephrectomy, and grade ≥2 acute kidney injury was not observed. High tumor complexity was the only independent predictor of acute kidney injury. Estimated glomerular filtration rate in patients with acute kidney injury improved within 1 year, and annual estimated glomerular filtration rate changes were similar among patients with or without acute kidney injury. Ultimately, 13 (5.0%) patients showed postoperative renal impairment during the median follow-up period of 37 months. Advanced age and diabetes mellitus were independent risk factors for renal impairment, but acute kidney injury was not. Conclusions The incidence and severity of acute kidney injury after clampless partial nephrectomy are low. Low-grade acute kidney injury after clampless partial nephrectomy does not seem to affect intermediate-term renal function.
- Published
- 2018
- Full Text
- View/download PDF
49. Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm
- Author
-
Yosuke Yasuda, Minato Yokoyama, Kosei Kudo, Yoh Matsuoka, Itsuo Kumazawa, Yasuhisa Fujii, Kazutaka Saito, Junichiro Ishioka, Sho Uehara, Soichiro Yoshida, Noboru Numao, Kazunori Kihara, Tomo Kimura, and Toshiki Kijima
- Subjects
Adult ,Male ,Prostate biopsy ,Urology ,CAD ,Convolutional neural network ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Image Interpretation, Computer-Assisted ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,medicine.diagnostic_test ,Receiver operating characteristic ,business.industry ,Deep learning ,Prostate ,Prostatic Neoplasms ,Magnetic resonance imaging ,Middle Aged ,Magnetic Resonance Imaging ,Data set ,Computer-aided diagnosis ,Area Under Curve ,030220 oncology & carcinogenesis ,Neural Networks, Computer ,Artificial intelligence ,business ,Algorithm ,Algorithms - Abstract
OBJECTIVE To develop a computer-aided diagnosis (CAD) algorithm with a deep learning architecture for detecting prostate cancer on magnetic resonance imaging (MRI) to promote global standardisation and diminish variation in the interpretation of prostate MRI. PATIENTS AND METHODS We retrospectively reviewed data from 335 patients with a prostate-specific antigen level of
- Published
- 2018
- Full Text
- View/download PDF
50. Prognostic significance of radiologic infiltrative feature of primary renal tumor in metastatic renal cell carcinoma
- Author
-
Y. Yamaguchi, S. Fukuda, Yasuhisa Fujii, Hiroshi Tanaka, Steven C. Campbell, Minato Yokoyama, Yoh Matsuoka, Yosuke Yasuda, Sho Uehara, Soichiro Yoshida, and Hiroshi Fukushima
- Subjects
Pathology ,medicine.medical_specialty ,Renal cell carcinoma ,Feature (computer vision) ,business.industry ,Urology ,medicine ,Renal tumor ,medicine.disease ,business - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.